N/A
N=15
Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study
Nicotine Dependence
Bottom Line
View on ClinicalTrials.gov: NCT04231539 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Maximum Concentration of Nicotine in Plasma (Cmax) — 5.7; 11.8; 6.7; 8.1 ng/mL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Nicotine (Drug); Vaporizer Device (Device); Salt-HIgh Nicotine Unflavored (Product B) (Drug); Free-Low Nicotine Tobacco Flavored (Product C) (Drug); Salt-High Nicotine Tobacco Flavored (Product D) (Drug)
- Age
- Adult · 21+ yrs
- Sex
- All
- Sponsor
- Roswell Park Cancer Institute
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Concentration of Nicotine in Plasma (Cmax) |
5.7; 11.8; 6.7; 8.1 | — |
| PRIMARY Area Under the Concentration-time Curve (AUC) |
128.8; 295.6; 177.3; 199.7 | — |
| PRIMARY Time to Maximum Concentration |
11.5; 9.8; 11.7; 8.6 | — |
| SECONDARY Perceived Harshness of Experimental Product Sampled |
4.85; 2.92; 4.62; 3.08 | — |
| SECONDARY Perceived Satisfaction of Experimental Product Sampled |
3.08; 3.75; 3.77; 4.23 | — |
| SECONDARY Perceived Liking of Experimental Product Sampled |
45.9; 55.2; 46.5; 52.5 | — |
| SECONDARY Minnesota Nicotine Withdrawal Scale Change (Change From Pre- to Post-) |
0.5; 0.7; 1.5; -0.5 | — |
Summary
This trial studies activity of time (pharmacokinetics), subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or e-liquids. This study aims to determine and compare the levels of nicotine delivered to the bloodstream from nicotine salt and free-base nicotine e-liquid solutions.
Eligibility Criteria
Inclusion Criteria
- Willingness to abstain from using ENDS product for 8-10 hours (overnight abstinence) prior to study visits
- Current daily ENDS user as determined by
- Has used ENDS product every day for the past 6 months (by history)
- Has used ENDS product or e-liquid containing nicotine (by history)
- Participant or legal representative must understand the investigational nature of this study and sign and Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria
- Smoked cigarettes in the past 7 days
- Currently smokes >= 5 cigarettes per month
- Unstable medical conditions (such as unstable heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, or glaucoma) or psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder) or current regular use of psychiatric medications (such as major tranquilizers and antidepressants)
- History of serious side effects from nicotine or from any nicotine replacement therapies
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or nursing females
- Concurrent participation in another clinical trial
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate
Data sourced from ClinicalTrials.gov (NCT04231539). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.